Member Info for Bermudashorts

Yes - if you had to list areas of growth next year then pharmacovigilance must surely be up there.

Merry Christmas to you too Sheephatch.

Sorry, meant to add this link

https://www.otcmarkets.com/stock/SCNLF/quote

The history behind the US OTC listing goes back a few years. As I understand it, it's simply down to the fact that a broker took it upon himself to offer Scancell stock on the OTC grey market. It's completely unregulated and separate from Pink Sheets.

.......and can you let Scancell know so they can crack on with trials :)

New peer reviewed research has been published today in the Cancers Journal. It appears to be a collaborative effort from researchers at Leiden University, Scancell and UoN . The authors are reviewing the current landscape and looking at the potential of tumour associated glycans in tumour imaging for surgery. Certainly worth a read of the intro and conclusion (see except below) and Scancell's mAbs get a mention too.

Back in August the same Leiden researchers conjugated Scancell's FG88.2/CH88.2 mAbs with infrared fluorescent dye and targeted a selection of gastrointestinal tumours. The idea being that they would bind to Lewisa/c/x glycans on the tumour surface and deliver their payload of dye so surgeons would be able to see the tumour tissue to be removed and distinguish it from healthy tissue.

'glycan targeting, while remaining challenging, potentially offers major advantages over protein targeting for imaging and
therapy. Several promising targeting moieties are currently available, of which some have been already evaluated for imaging and therapeutic purposes. In this review, we summarized the ongoing research within the field of glycan imaging and intended to provide a firm foundation for glycan-based improvement of cancer care in the near future'

https://www.mdpi.com/2072-6694/12/12/3870

Ruck,

Thanks for that, have no recollection of that conversation, too much going on atm and brain like a sieve so apologies, you obviously have tried to discuss on the bb.

Excellent post thanks Ivy. Hope UoN are able to fast track development of the delivery system and we will start seeing a steady stream of news here, ie. completion of manufacture, clinical trial approval from MHRA and then 1st patient dosed. The phase I trial and results should be very quick - a completely different ball game to oncology trials.

The other point which I haven't seen discussed at all yet was the suggestion from Lindy Durrant that SN14 could be used in combination with other vaccines.............intriguing.

........or Santa rally created by progress in Scancell's labs thanks to hard work and brilliance from Lindy Durrant and her team!

Burble/Ivy,

As I understand it, the phase I trial will be primarily all about safety and will also provide valuable data re. immune response - it'll just be carried out in healthy volunteers who haven't yet been vaccinated with any other candidate. It won't be randomised, so whether or not we're in the middle of a third wave shouldn't really make any difference should it? ie. Isn't the level of community spread only a factor when you're running randomised trials?

Best case scenario here IMO is that Scancell run a successful phase I and then license to big pharma for phase II/III, allowing them to take over from the earliest stages of planning and design through to execution of a phase II/III trial.

Burble - I have emailed CH this morning with the same question - will let you know if I get a reply.

Ray - not sure re. the prospect of a single shot dose. There has been no mention of it so far and whilst it would be great, it's highly unlikely that any 2nd gen vax is going to overcome every single issue. If SN14 performs in trials as hoped, the fact that it would offer the potential for a much longer duration of immunity and protection over mutated forms of the virus would be a huge step forward in a world that will already be set up for a two dose vaccination programme by then in any case.

Chelsea/Ruck,

Even putting the CLNs to one side and looking at pure equity funding, Redmile only bought £5m at 5.5p in the first funding round - they then followed that with a purchase of £12.1m at 13p.

I have no idea what their average is, but the vast majority of their holdings in terms of both equity purchases and CLNs are at 13p. Always good to see an institutional investor averaging up.

billbrown,

You may not be a frequent visitor here but another useful and relevant link - thanks. Surface oncology seem to have bagged themselves a cracking deal for a preclinical mAB which isn't even IND ready yet.

LL,

My parents were both vaccinated today and experienced none of the problems mentioned in previous posts. Not only was plenty of additional parking laid on, but stewards were directing people to parking spaces and the entrances appropriate to their needs (steps/ramps etc.). Despite being incredibly busy, the whole thing was very well organised and everybody was monitored for 15 minutes after their jab before they were allowed to leave.

So let's hope that Ruck's parents experience was the exception rather than the norm.

Very much sounds like it.

Lindy Durrant's work is cited in a recent article from researchers at Lyon and Montreal universities. The article was published last week and is looking at new sources of tumour specific antigens for immunotherapy. The section 'Tumor-Specific Antigen Derived From Post-Translation Modifications' is worth a read and gives some insight into the potential of the Moditope platform. Of particular note:-

'Citrullination levels seems to be higher in ovary, uterus, colon, bladder, breast, liver, lung, esophagus, kidney, and prostate tumors than in their corresponding normal tissues due to the overexpression of either PAD4 or PAD2 (161–163). Although the presentation of citrullinated MAPs on MHC I molecules has never been demonstrated, citrullination was shown to increase peptides binding affinity for HLA-DRB1 (a MHC class II allele) (164, 165) which could then be recognized by both mice and human repertoires of “cytotoxic” CD4+ T cells (166–168).'

References 161 and 168 are to Moditope research from Scancell.

https://www.frontiersin.org/articles/10.3389/fimmu.2020.583287/full

Interview with Joe Wiley below

https://www.youtube.com/watch?v=kutZbMQ_i0s

WTP

You're making quite a few assumptions there:-

1) If Scancell wanted/needed an extra £5m or £10m then they would have asked for it - they didn't. They requested the amount they needed to complete preclinical development and initiate phase I trials and that's what they got. They can and I'm sure will apply for follow on funding as and when it's required, just as Oxford did.

2) You have no way of knowing whether extra staff would have helped speed up development - it appears that timescales are being driven by manufacture and development of the delivery system, both of which are being carried out by other parties.

3) Regarding timescales - agree, it took a while but they were following the same UKRI application procedure and subject to review by an independent panel of experts, just like everyone else.

4) Scancell didn't have to bring out the begging bowl for the Sky interview- that was down to David Evans

5) Of course there wasn't the same level of urgency, Scancell announced from outset that this would be a second generation vaccine. Having said that, you don't know when they applied but the longest it can have taken is 4 months from application to allocation of funds. We know for certain that UKRI had to go back with some queries and in terms of how long these applications usually take, 4 months is actually very quick.

6) No, Scancell could never have matched the scale and speed of development of BioNTech , not in a million years. I'm happy to explain why if you want.

7) Your views on the Government, how they have wasted money etc. are irrelevant in the context of this debate (although I happen to agree with you). The process for applying for and allocation of these funds was down to UKRI, not Boris Johnson

IMO The UKRI funding award was a great achievement for Scancell as well as recognition of Lindy Durrant's expertise. These posts which suggest Scancell have somehow been short changed or treated as a second class candidate by the Gov. fail to recognise that - don't forget Scancell were awarded more or less the same amount as Oxford received at the same stage. They did brilliantly to get such a large award and hopefully preclinical development of Covidity will go well and they'll be in a position to apply for more.

WTP/Chelsea

I know we've had this discussion before, but why does the Government need extra impetus to back Scancell? They've already backed them!

Yes, seems like a good match and particularly like these bits:-

'Acquisition expected to be immediately accretive and earnings enhancing'

'The acquisition will be funded using the Company’s existing cash resources without significant depletion of cash available to fund future organic and inorganic growth.'

Chelsea,

Average price for Redmile atm is around 8.5p but they have nearly £18m of CLNs at 13p.

Vulpes, haven't checked but assume it's somewhere around 5.5p to 6p.